Asymmetric Dimethylarginine and Adiponectin After Renal Transplantation: Role of Obesity

Teplan, Vladimı́r; Schück, O; Ráček, Jaroslav; Siroka, Romana; Haluzı́k, Martin; Kudla, Michal; Vı́tko, Štefan

doi:10.1053/j.jrn.2007.10.030

Cited by 12 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, we observed a significant increase in ADMA levels and a decrease in methylation activity in transplant recipients compared to a control population [92]. Other authors have suggested that obesity after RTx may be directly associated with elevated ADMA levels and a decrease in adiponectin, increasing cardiovascular risk [100,101]. Moreover, ADMA was found to be a significant risk factor for graft failure, so these plasma levels could predict morbidity, mortality and the deterioration of graft function RTx [102].…”

Section: Asymmetric Dimethylarginine In Kidney Diseasementioning

confidence: 85%

Asymmetric Dimethylarginine, Endothelial Dysfunction and Renal Disease

Aldámiz‐Echevarría

Andrade

2012

IJMS

View full text Add to dashboard Cite

l-Arginine (Arg) is oxidized to l-citrulline and nitric oxide (NO) by the action of endothelial nitric oxide synthase (NOS). In contrast, protein-incorporated Arg residues can be methylated with subsequent proteolysis giving rise to methylarginine compounds, such as asymmetric dimethylarginine (ADMA) that competes with Arg for binding to NOS. Most ADMA is degraded by dimethylarginine dimethyaminohydrolase (DDAH), distributed widely throughout the body and regulates ADMA levels and, therefore, NO synthesis. In recent years, several studies have suggested that increased ADMA levels are a marker of atherosclerotic change, and can be used to assess cardiovascular risk, consistent with ADMA being predominantly absorbed by endothelial cells. NO is an important messenger molecule involved in numerous biological processes, and its activity is essential to understand both pathogenic and therapeutic mechanisms in kidney disease and renal transplantation. NO production is reduced in renal patients because of their elevated ADMA levels with associated reduced DDAH activity. These factors contribute to endothelial dysfunction, oxidative stress and the progression of renal damage, but there are treatments that may effectively reduce ADMA levels in patients with kidney disease. Available data on ADMA levels in controls and renal patients, both in adults and children, also are summarized in this review.

show abstract

Section: Asymmetric Dimethylarginine In Kidney Diseasementioning

confidence: 85%

Asymmetric Dimethylarginine, Endothelial Dysfunction and Renal Disease

Aldámiz‐Echevarría

Andrade

2012

IJMS

View full text Add to dashboard Cite

show abstract

“…The following possible explanations may be offered: (a) There may be an enhanced tendency for an altered response to anti‐rejection therapy; for example, cyclosporine is lipophilic and is thus preferentially distributed to adipose‐rich tissues 17 . (b) There may be obesity‐related increases in nitric oxide synthase inhibitors, leading to vascular dysfunction and a reduction in adiponectin, 18 which has anti‐atherosclerotic and anti‐inflammatory properties 19 : indeed, reduced pre‐transplantation adiponectin levels have been shown to be associated with allograft failure 20 . (c) Obesity has been associated with a prothrombotic and inflammatory state, which has been implicated in the rejection process 21 …”

Section: Discussionmentioning

confidence: 99%

Weight gain post–heart transplantation is associated with an increased risk for allograft vasculopathy and rejection

Ram

Klempfner

Peled

et al. 2020

Clinical Transplantation

View full text Add to dashboard Cite

OBJECTIVE Obesity and overweight are associated with an increased risk for cardiovascular disease. Since fat mass (FM) and fat‐free mass (FFM) both contribute to total body weight (TBW), we characterized the post–heart transplantation (HT) change in TBW and its implications for outcomes. METHODS Post‐HT changes in TBW, FM, and FFM were reviewed for 211 HT patients assessed during 1997–2017. Endpoints included cardiac allograft vasculopathy (CAV) and rejection. RESULTS Median TBW increased by 7.3% at 1 year, with a significant rise in the obese category (28% vs. 13%, p < 0.001) and with FM versus FFM making the main contribution (23% vs. 3%, p < 0.001). When patients were divided according to median TBW change (“high” vs. “low”), Kaplan–Meier analysis showed that 10‐year freedom from CAV (log‐rank p < 0.005) and rejection (log‐rank p < 0.01) was significantly higher for the “low” TBW change group. Consistently, multivariable analyses showed that the “high” group was independently associated with significant 3.5‐fold and 4.2‐fold increased risks for CAV (95% CI 1.4–8.7, p = 0.01) and rejection (95% CI 1.2–15.4, p = 0.03), respectively. CONCLUSIONS Weight gain, contributed mostly by FM, is independently associated with an increased risk for CAV and rejection. Follow‐up emphasis should be placed on weight gain and preventative measures.

show abstract

“…According to some authors, in patients without chronic renal failure, elevated leptin compared with adiponectin is characteristic of metabolic syndrome and correlated with high risk of CVDs [19e21]. Teplan et al [22] showed decreased levels of adiponectin and concluded that obesity after renal transplantation is associated with increased asymmetric dimethylarginine and decreased adiponectin in plasma.…”

Section: Discussionmentioning

confidence: 99%